Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Amantadine: adverse event reports

All products with this active ingredient · not in an FDA-approved animal drug

493reports naming this ingredient, 2007–20260% of all reports · about 27 a year
132reports, 12 months to March 2026186 in the 12 months before
57.9%classed serious, as reportedof 492 reports stating it
21.5%record death or euthanasia, as reported106 reports
99%of reports concern dogs0.1% of all dog reports

FDA has received 493 adverse event reports in which a drug is recorded with amantadine as its active ingredient, from October 2007 to March 2026. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 132 reports named it, down 29% from 186 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 27 reports a year and 0% of all 1,357,245 reports (0.1% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed death by euthanasia (15.6%), lethargy (13.2%) and vomiting (11.2%). A report can list several signs, so shares add to more than 100%; 645 different terms appear across these reports.

99% of reports concern dogs. Not every report describes illness: 16.6% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 57.9% were classed as serious, and 21.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog425 · peak 23
May 2021: 1Jun 2021: 2Jul 2021: 2Aug 2021: 1Sep 2021: 1Dec 2021: 2Jan 2022: 2Feb 2022: 1May 2022: 2Jul 2022: 1Aug 2022: 4Sep 2022: 2Nov 2022: 3Dec 2022: 2Jan 2023: 1Feb 2023: 1Apr 2023: 3Jun 2023: 2Aug 2023: 1Sep 2023: 2Oct 2023: 6Nov 2023: 10Dec 2023: 23Jan 2024: 14Feb 2024: 12Mar 2024: 11Apr 2024: 21May 2024: 9Jun 2024: 11Jul 2024: 11Aug 2024: 19Sep 2024: 19Oct 2024: 9Nov 2024: 13Dec 2024: 23Jan 2025: 20Feb 2025: 17Mar 2025: 12Apr 2025: 17May 2025: 17Jun 2025: 12Jul 2025: 17Aug 2025: 11Sep 2025: 8Oct 2025: 8Nov 2025: 9Dec 2025: 8Jan 2026: 6Feb 2026: 10Mar 2026: 62022202320242025
Cat5 · peak 2
Apr 2024: 1Mar 2025: 1Nov 2025: 1Dec 2025: 22022202320242025
Horse0 · peak 1
2022202320242025
Other0 · peak 1
2022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

0871732007: 120072012: 320122013: 620132014: 220142015: 620152016: 320162017: 1220172018: 820182019: 520192020: 1620202021: 1020212022: 1720222023: 4920232024: 17320242025: 16020252026: 222026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of amantadine reports listing the termall dog reports

  1. Death by euthanasia[the animal was euthanized]15.6%77
  2. Lethargy[unusually tired or inactive]13.2%65
  3. Vomiting11.2%55
  4. Diarrhoea[diarrhea]10.3%51
  5. Ataxia[unsteady, uncoordinated movement]8.5%42
  6. Lack of efficacy - NOS[the product did not have the expected effect]7.9%39
  7. Polydipsia[drinking more than usual]7.9%39
  8. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]7.3%36
  9. Polyuria[passing more urine than usual]7.3%36
  10. Partial lack of efficacy[the product worked less well than expected]6.7%33
  11. Anorexia[not eating]6.3%31
  12. Proprioception deficit[reduced awareness of limb position]6.3%31
  13. Death5.7%28
  14. Pain NOS[NOS: not otherwise specified]5.5%27
  15. Hind limb paresis[weak hind legs]5.3%26
  16. Seizure NOS[seizure, type not specified]5.3%26
  17. Weakness5.1%25
  18. Anaemia NOS[low red blood cell count]4.7%23
  19. Panting4.7%23
  20. Lameness4.5%22
  21. Other abnormal test result NOS[abnormal laboratory result, type not specified]4.3%21
  22. Elevated serum alkaline phosphatase (ALP)[a liver and bone enzyme above the normal range]3.9%19

Top 30 of 645 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal11.6%57
Recovered with Sequela0.2%1
Ongoing49.1%242
Died6.1%30
Euthanized15.4%76
Outcome Unknown17.8%88

What kind of report it was

Safety issue82.2%405
Lack of expected effectiveness7.1%35
Both safety and lack of expected effectiveness9.5%47
Manufacturing or product defect1.2%6
Other0%0

Coloured bar: reports naming amantadine. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog99%488
Cat1%5

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year0%0
1 to 3 years0.8%4
4 to 7 years8.9%44
8 to 11 years34.9%172
12 years and over54.6%269
Age not given0.8%4

Weight of the animal

Under 5 kg (11 lb)4.3%21
5 to 9.9 kg (11–22 lb)4.7%23
10 to 24.9 kg (22–55 lb)26.2%129
25 to 44.9 kg (55–99 lb)54%266
45 kg and over (99 lb+)8.3%41
Weight not given2.6%13

Route of administration stated in reports: oral (204), subcutaneous (1).

In context

MeasureAmantadineAll dog reportsAll reports
Reports493985,6751,357,245
Share of that pool's reports naming this drug—0.1%0%
Classed serious, of reports stating it57.9%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports2155563.8
Filed as lack of expected effectiveness (wholly or partly)16.6%—23%
Top term, share of reportsDeath by euthanasia 15.6%2.3%—

This set accounts for 100% of all reports naming amantadine, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about amantadine reports

How many adverse event reports has FDA received for amantadine?

493 reports record a drug with amantadine as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 132 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

death by euthanasia (15.6%), lethargy (13.2%), vomiting (11.2%), diarrhoea (10.3%) and ataxia (8.5%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (99%) and cat (1%). Among single-breed animals the most frequent labels are Labrador Retriever, German Shepherd Dog, Golden Retriever and American Pit Bull Terrier; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

132 reports in the 12 months to March 2026, down 29% from 186 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that amantadine harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of amantadine?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.